Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P47804

UPID:
RGR_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P47804; A6NKK7; Q96FC5

BACKGROUND:
The RPE-retinal G protein-coupled receptor is essential for phototransduction, the process by which light is converted into electrical signals in the retina. It specifically binds to retinal, facilitating its isomerization, which is crucial for vision. This receptor's unique role underscores its importance in the visual cycle.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in vision, mutations in the gene encoding the RPE-retinal G protein-coupled receptor are implicated in Retinitis pigmentosa 44. This disease leads to severe visual impairment due to the degeneration of photoreceptors. Exploring the receptor's mechanisms offers a promising avenue for developing targeted therapies that could restore vision or halt the progression of retinal dystrophies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.